JP2011505381A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505381A5
JP2011505381A5 JP2010536228A JP2010536228A JP2011505381A5 JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5 JP 2010536228 A JP2010536228 A JP 2010536228A JP 2010536228 A JP2010536228 A JP 2010536228A JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5
Authority
JP
Japan
Prior art keywords
region
seq
antibody
segment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010536228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505381A (ja
JP5781765B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/085196 external-priority patent/WO2009073631A2/en
Publication of JP2011505381A publication Critical patent/JP2011505381A/ja
Publication of JP2011505381A5 publication Critical patent/JP2011505381A5/ja
Application granted granted Critical
Publication of JP5781765B2 publication Critical patent/JP5781765B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010536228A 2007-11-30 2008-12-01 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体 Expired - Fee Related JP5781765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
US60/991,679 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (3)

Publication Number Publication Date
JP2011505381A JP2011505381A (ja) 2011-02-24
JP2011505381A5 true JP2011505381A5 (enExample) 2012-01-26
JP5781765B2 JP5781765B2 (ja) 2015-09-24

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536228A Expired - Fee Related JP5781765B2 (ja) 2007-11-30 2008-12-01 シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体

Country Status (15)

Country Link
US (3) US8044181B2 (enExample)
EP (1) EP2220117A2 (enExample)
JP (1) JP5781765B2 (enExample)
KR (1) KR20100097719A (enExample)
CN (1) CN101910197B (enExample)
AU (1) AU2008333985B2 (enExample)
BR (1) BRPI0819598A2 (enExample)
CA (1) CA2706732A1 (enExample)
EA (1) EA201000903A1 (enExample)
IL (1) IL206036A0 (enExample)
MX (1) MX2010005871A (enExample)
NZ (1) NZ586357A (enExample)
SG (1) SG186017A1 (enExample)
WO (1) WO2009073631A2 (enExample)
ZA (1) ZA201003852B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
EP2615172A1 (en) * 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101259239B1 (ko) 2008-01-10 2013-04-29 시오노기세야쿠 가부시키가이샤 ＰｃｒＶ에 대한 항체
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
PT2407537E (pt) * 2009-03-11 2015-02-17 Shionogi & Co Anticorpo pcrv humanizado com atividade anti-pseudomonal
JP2013515079A (ja) * 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
KR102111171B1 (ko) * 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
MX2017014002A (es) 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
HUE051896T2 (hu) 2015-07-16 2021-03-29 Inhibrx Inc Multivalens és multispecifikus DR5-kötõ fúziós fehérjék
CN110072554A (zh) * 2016-05-05 2019-07-30 宾夕法尼亚大学理事会 用于抗铜绿假单胞菌的dna抗体构建体
CA3108071A1 (en) * 2018-08-01 2020-02-06 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
PH12021552903A1 (en) * 2019-06-11 2022-04-04 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225552A (en) * 1880-03-16 Disintegrating-mill
US108565A (en) * 1870-10-25 Improvement in snow-plows
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
JP2000516452A (ja) 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
AU3580800A (en) * 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
AU2001238677A1 (en) 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP4355786B2 (ja) * 2001-01-26 2009-11-04 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスｖ抗原を用いる免疫化のための方法および組成物
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1479695B1 (en) * 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20090317329A2 (en) 2005-07-05 2009-12-24 Baker Idi Heart & Diabetes Institute Holdings Limited Anticoagulation agent and uses thereof
CA2635445A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR101351208B1 (ko) 2006-06-21 2014-01-14 온코세라피 사이언스 가부시키가이샤 Ｆｚｄ10에 대한 종양-표적화 모노클로날 항체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP5781765B2 (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
US12428473B2 (en) Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
JP2011505381A5 (enExample)
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
US20150284450A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
HK1201453B (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
NZ722379B2 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules